The effects in correction of anaemia in chronic kidney disease with erythropoietin therapy - preference to cardiovascular, neurologic and general well-being of patients from a tertiary care centre

Journal of the Indian Medical Association

Volumn 110, Issue 12, 2012, Pages 885-888

  Mukhopadhyay, Prasanta ^a   Sinha, Uma ^a   Banerjee, Jasamalya ^a   Choudhury, Atanu Roy ^a,b   Philips, Cyriac Abby ^a  

^a NRS MEDICAL COLLEGE   (India)

^b NORTH BENGAL MEDICAL COLLEGE   (India)

Author keywords

Anaemia; Chronic renal disease; Cognition; Ejection fraction; Erythropoietin therapy; General well being; Left ventricular mass index

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY DISEASE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NERVOUS SYSTEM FUNCTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TERTIARY HEALTH CARE; UREA NITROGEN BLOOD LEVEL; URINALYSIS; WELLBEING;

EID: 84872224480     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Eschbach J, Deoreo P, Ademson J. rHuEPO clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997; 30: S192-240.
2. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. Am Soc Nephrol 2002; 13: 504-10.
3. Self KG, Conrady MM, Eichner ER. Failure to diagnose anemia in medicine patients. Am J Med 1986; 31: 786-90.
4. Loge JP, Lange RD, Moore CV. Characterization of the anemia associated with chronic renal insufficiency. Am J Med 1958; 24: 4-18.
5. Peto TE, Hershko C. Iron and infection. Baillieres Clin Haematol 1989; 2: 435-58.
6. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1309-16.
7. Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 1999; 14: 29-36.
8. London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. Adv Ren Replace Ther 1997; 4: 194-211.
9. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35: S117-31.
10. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis 2001; 38: 109-17.
11. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
12. Löw-Friedrich I, Grützmacher P, März W, Bergmann M, Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54-60.
13. Martinez-Vea A, Bardají A, García C, Ridao C, Richart C, Oliver JA. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 1992; 19: 353-7.
14. Silberberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4.